Discovery of effective phosphodiesterase 2 inhibitors with antioxidant activities for the treatment of Alzheimer’s disease
- 1 June 2021
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 41, 128016
Abstract
No abstract availableKeywords
Funding Information
- Guangdong Provincial Natural Science Foundation
- China Postdoctoral Science Foundation
- National Natural Science Foundation of China
- Pearl River S and T Nova Program of Guangzhou Municipality
This publication has 27 references indexed in Scilit:
- PDE2 inhibition: Potential for the treatment of cognitive disordersBioorganic & Medicinal Chemistry Letters, 2013
- Synthesis and biological evaluation of berberine–thiophenyl hybrids as multi-functional agents: Inhibition of acetylcholinesterase, butyrylcholinesterase, and Aβ aggregation and antioxidant activityBioorganic & Medicinal Chemistry, 2013
- Design, Synthesis, and Evaluation of Multitarget-Directed Resveratrol Derivatives for the Treatment of Alzheimer’s DiseaseJournal of Medicinal Chemistry, 2013
- Discovery of a new series of [1,2,4]triazolo[4,3-a]quinoxalines as dual phosphodiesterase 2/phosphodiesterase 10 (PDE2/PDE10) inhibitorsBioorganic & Medicinal Chemistry Letters, 2013
- Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissuesNeuropharmacology, 2010
- Multi-target-Directed Ligands To Combat Neurodegenerative DiseasesJournal of Medicinal Chemistry, 2008
- A Century of Alzheimer's DiseaseScience, 2006
- Cyclic Nucleotide Phosphodiesterases: Molecular Regulation to Clinical UsePharmacological Reviews, 2006
- Extending Applicability of the Oxygen Radical Absorbance Capacity (ORAC−Fluorescein) AssayJournal of Agricultural and Food Chemistry, 2003
- Long-lasting forms of synaptic potentiation in the mammalian hippocampus.Learning & Memory, 1996